Women’s healthcare is the need of the hour due to the growth in the diseases and complications caused to the women in the current scenario. The women healthcare includes complete emphasis and focus over the wellbeing of the women by ensuring appropriate diagnosis and treatment. Women experience various problems during and postmenstrual cycle, which is common amongst women. Furthermore, the diseases which are mostly prevalent among the women include various urological disorders, poly cystic ovarian syndrome and other post-menopausal complications. There are various medications which are available for controlling the birth and also for the regulation of hormones, which is a major challenge. During pregnancy and post-pregnancy the hormonal disturbances are experienced by the majority of women, the management of which are important and is in demand for the next few years.
COVID-19 scenario analysis:
Coronavirus disease 2019 (COVID-19) has created an economic crisis along with a health care crisis. COVID-19 pandemic has brought an enforced lockout which stopped major sectors from earning revenue and hence led to the recession in the current scenario. The Covid-19 pandemic has a severe impact on the healthcare system, causing in 50% to 70% drop in revenue from March. There is a shut-down of many small hospitals, clinics and nursing homes to stop the spread of the disease. The law also forced the doctors to reduce the number of surgical procedures in this duration. In addition, visa cancellations have led to a reduction in medical tourism and can negatively impact the healthcare services market growth.
Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis
The key factors that are anticipated to help the market grow include rise in concern of the government for controlling population inflation and increase in the incidences of chronic health conditions such as endometriosis and urinary incontinence. The surge in the R&D of the women’s healthcare products and increase in the demand for the medications, which are used to prevent the unintended pregnancies would help the market propel in the coming years. However, the rising product recalls may hinder the growth of industry for the commenced period.
New product launches to flourish the market
The key market players are focusing over the development of the products and hence, gain attention to attain maximum revenue in the forecast period. For instance, in June 2019, U.S. Food and Drug Administration declared that it approved Vyleesi. This was claimed to assist in the treatment of generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. The rise in the product approvals and the government concern for the development of such products would boost the market
Furthermore, in February 2020, Agile Therapeutics, Inc., which is amongst the women’s healthcare company, announced that the U.S. Food and Drug Administration (FDA) approved Twirla transdermal system. This is indicated as a method of contraception for usage in women of reproductive potential with a BMI < 30 kg/m2 for whom a combined hormonal contraceptive.
Surge in mergers and acquisitions to boost the market
The market leaders are focusing to enhance their presence in the market by getting into definitive agreements with the other key leaders. For instance, in July 2019, Pfizer declared that it had acquired Matrix Pharma, which has various products in anti-HIV and women’s health categories. In addition, the combination of two companies in India is expected to be around $500 million, and it might help Pfizer to get to the number 10th position in the $5 billion Indian pharma market, was according to figures from AWACS, a pharma consulting firm.
Furthermore, in October 2017, Lupin acquired women’s health company in the U.S. for approximately $150 million. The complete acquisition of Symbiomix and the ‘Solosec’ franchise would help Lupin to expand its women’s health specialty business and hence, gain maximum shares in the market. Lupin is expected to pay $50 million upfront and the residual amount about $100 million over the coming years.
Key benefits of the report:
- This study presents the analytical depiction of the global Women’s Healthcare Care industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global Women’s Healthcare Care market share.
- The current market is quantitatively analyzed to highlight the global Women’s Healthcare Care market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed global Women’s Healthcare Care market analysis based on competitive intensity and how the competition will take shape in coming years.
Questions answered in the Women’s Healthcare Care Market research report:
- What are the leading market players active in the Women’s Healthcare Care market?
- What the current trends will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the market?
- What are the projections for the future that would help in tasking further strategic steps?
Womens Healthcare Care Market, by Drug Report Highlights
| Aspects | Details |
 By Drug |
|
 By Application |
|
 By Distribution channel |
|
 By Region |
|
 Key Market Players | Pfizer Inc.,, Agile Therapeutics Inc.,, Mylan N.V.,, Amgen,, Lupin,, Bayer AG,, Apothecus Pharmaceutical,, Merck & Co., Blairex Laboratories., Ferring Pharmaceuticals, |
Loading Table Of Content...
